MedTrace Logo

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

NCT02320773 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 863

Last updated 2024-10-31

No results posted yet for this study

Summary

A study to understand the impact of Betmiga® on patients quality of life, satisfaction with treatment, how long patients remain on treatment, patterns of healthcare resource utilisation, and safety as prescribed by the physicians in routine clinical practice.

Conditions

  • Urgency Incontinence
  • Urinary Bladder Overactive
  • Overactive Bladder
  • Urologic Diseases
  • Urinary Bladder Diseases

Interventions

DRUG

Betmiga®

Oral

Sponsors & Collaborators

  • Astellas Pharma Europe Ltd.

    lead INDUSTRY

Principal Investigators

  • Medical Affairs Europe · Astellas Pharma Europe Ltd.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-25
Primary Completion
2016-07-27
Completion
2016-07-27

Countries

  • Czechia
  • Denmark
  • Greece
  • Ireland
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02320773 on ClinicalTrials.gov